Drug Profile
HPP 404
Alternative Names: HPP404Latest Information Update: 28 Jul 2015
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer vTv Therapeutics
- Class Anorectics; Obesity therapies; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 14 Jul 2014 High Point Pharmaceuticals terminates a phase II trial in Obesity in USA (NCT01540864)
- 29 Aug 2012 High Point Pharmaceuticals completes enrolment in its phase II trial for Obesity in USA (NCT01540864)
- 09 May 2012 Phase-II clinical trials in Obesity in USA (PO)